Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid

Affiliations

• ¹ University of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
• ² Hospital Group Twente, Dept of Clinical Pharmacy, Almelo and Hengelo, The Netherlands.
• ³ University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands.
• ⁴ University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
• ⁵ University of Groningen, University Medical Center Groningen, Dept of Internal Medicine, Groningen, The Netherlands.
• ⁶ Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
• ⁷ Westmead Hospital, Sydney, Australia.
• ⁸ Marie Bashir Institute of Infectious Diseases and Biosecurity, Sydney, Australia.